Founded in 2010, Mercia Fund Management is a Henley-in-Arden, United Kingdom based venture capital firm. They look to invest in early-stage technology start-ups located in the West Midlands. Their initial investment is typically between £50,000 and £250,000 and they have the capacity to follow on with a limit of £1 million investment per company.
Mercia Fund Management manages £12.8 million funds under management raised from a mixture of public and private sector fund investors.
Mercia Fund Management has made investments in Invizius, GeckoLabs, PHARMASEAL, ClinSpec Diagnostics, BlackCurve, Quick Reach, Cyan Forensics, Notify Technology, Chromition, Tungl, Kumulos, ArcVehicle, Adapttech, Sugdens and Pertinax Pharma Ltd.
Oxford Genetics is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.
nanoTherics is a company in the pharmaceuticals industry.
Head of Marketing & Communication, Senior Management Team
Group Financial Controller, Senior Management Team
EIS Client Services Associate
Dr Alistair Forbes
Investment Director, Head of Software & the Internet
Dr Graham Davies
Dr Isabel Dodd
Dr. Nicola Broughton
Investment Director, Head of Universities
Marketing Graphics and Even Coordinator
Funds, Investment Committee Member /Chair
Fund Principal, Senior Management Team
Chief Financial Officer